{
    "clinical_study": {
        "@rank": "117494", 
        "arm_group": [
            {
                "arm_group_label": "intravenous haloperidol", 
                "arm_group_type": "Active Comparator", 
                "description": "intravenous haloperidol pharmacokinetics"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This will be a blinded study to compare the absorption of topical haloperidol with placebo"
        }, 
        "brief_title": "Evidence of Haloperidol Absorption After Topical Administration", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Nausea", 
            "Vomiting", 
            "Palliative Care"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Age: patient must be 18 years or older and less than 70 years of age.\n\n          -  Provision of informed consent\n\n          -  No previous adverse reaction to haloperidol\n\n          -  No current use of haloperidol\n\n          -  Good health\n\n          -  No alcohol within 24 hours of the study\n\n          -  No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal,\n             hepatic or pulmonary disease.\n\n          -  Normal neurologic exam\n\n        Exclusionary Criteria\n\n          -  Evidence of any other significant clinical disorder or laboratory finding that makes\n             it undesirable for the patient to participate in the study\n\n          -  Recent cerebral trauma\n\n          -  Study will exclude women who are pregnant and/or nursing\n\n          -  Women who are of child bearing potential must have a negative urine pregnancy test.\n\n          -  History of seizures\n\n          -  Taking medications that can interact with haloperidol\n\n          -  Subjects with significant cardiovascular (cardiac conduction deficits),\n             gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684969", 
            "org_study_id": "11-005661"
        }, 
        "intervention": [
            {
                "arm_group_label": "intravenous haloperidol", 
                "description": "0.5 mg  iv x one dose", 
                "intervention_name": "Haloperidol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "0.5 mg iv , one dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Haloperidol", 
                "Haloperidol decanoate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Nausea", 
            "vomiting", 
            "gastrointestinal symptoms", 
            "palliative care"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Topical Haloperidol: Evidence of Absorption After Topical Administration", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Eric Prommer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Measuring either the presence of absence of haloperidol", 
            "measure": "To measure the pharmacokinetics levels of haloperidol after topical administration compared with intravenous administration.", 
            "safety_issue": "No", 
            "time_frame": "baseline to 240 minutes  after administration."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684969"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Eric E. Prommer", 
            "investigator_title": "Assistant Professor of Medicine,  College of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eric E. Prommer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013", 
        "why_stopped": "lack of accrual and funding is about to expire."
    }
}